Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

ESR1 Mutations Provide Window Into Breast Cancer Metastasis

May 27th 2022

Present in approximately two-thirds of estrogen receptor-positive breast cancers, the role of ESR1 mutations in disease metastasis is poorly defined.

Dr. Tarantino on the Importance of the DESTINY-Breast04 Trial in HER2-Low Breast Cancer

May 26th 2022

Paolo Tarantino, MD, discusses the importance of the phase 3 DESTINY-Breast04 trial in HER2-low breast cancer.

Black Patients Less Likely to Trust Clinical Trials in Breast Cancer

May 26th 2022

Black patients were less likely to be included in clinical trials that investigate newer treatments for metastatic breast cancer, despite having the highest death rate and shortest survival outcomes when compared with other racial and ethnic groups in the United States.

Tarantino Previews Exciting Research in HER2-Low Breast Cancer

May 26th 2022

Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.

Patient Profile 2: Strategies for Managing Brain Metastases in HER2+ Metastatic Breast Cancer

May 26th 2022

Shared insight on strategies for managing brain metastases in patients with HER2+ breast cancer.

Patient Profile 2: 26-Year-Old Woman With Triple Positive Breast Cancer

May 26th 2022

Shanu Modi, MD, presents the clinical scenario of a 26-year-old woman with triple positive breast cancer.

NICE Recommends Pembrolizumab Plus Chemotherapy for Metastatic PD-L1–Positive TNBC

May 26th 2022

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance recommending the approval of pembrolizumab plus chemotherapy for the treatment of patients with PD-L1–positive metastatic triple-negative breast cancer.

Poziotinib Provides Clinically Meaningful OS Benefit in Metastatic HER2+ Breast Cancer

May 25th 2022

Poziotinib prolonged overall survival in heavily pretreated Korean patients with HER2-positive metastatic breast cancer.

Selecting Novel Adjuvant Therapy For Patients With Breast Cancer

May 25th 2022

Following their discussion on the OlympiA and monarchE trials in breast cancer, experts consider when they would use olaparib or abemaciclib in the adjuvant setting.

Adjuvant Abemaciclib in Early Breast Cancer: The monarchE Trial

May 25th 2022

Shared insight on the monarchE trial, which studied adjuvant abemaciclib in patients with HR+, HER2- high-risk early breast cancer.

European Commission Approves Pembrolizumab Plus Chemotherapy for High-Risk Early-Stage TNBC

May 24th 2022

The European Commission approved pembrolizumab for use in combination with chemotherapy as neoadjuvant therapy, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence.

Hotspot ESR1 Mutations Drive Tumor Stickiness in Metastatic Endocrine-Resistant Breast Cancer

May 24th 2022

The prevalence of ESR1 mutations in endocrine-resistant metastatic breast cancer has paved an avenue for investigators to explore their role in the promotion of metastasis.

Clinical Benefit With Elacestrant Shines Spotlight on SERDs in ER+/HER2- Breast Cancer

May 23rd 2022

A significant improvement in progression-free survival has been reported with the oral selective estrogen receptor degrader elacestrant vs standard of care treatments for patients with estrogen receptor–positive, HER2-negative breast cancer.

Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

May 19th 2022

Expert perspectives on the use of trastuzumab deruxtecan in a patient with HER2+ metastatic breast cancer.

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

May 19th 2022

Breast medical oncologist, Tiffany Traina, MD, shares a clinical scenario of a patient with HER2+ metastatic breast cancer and discusses her treatment approach in the neoadjuvant, adjuvant, and metastatic settings.

Frontline Datopotamab Deruxtecan/Durvalumab Combo Elicits Encouraging Responses in TNBC

May 19th 2022

The combination of the TROP2-directed antibody-drug conjugate datopotamab deruxtecan and durvalumab showcased early activity with acceptable safety when used as first-line treatment in patients with locally advanced or metastatic triple-negative breast cancer, according to data from the phase 1b/2 BEGONIA trial.

CDK4/6 Inhibition and Surgery Endeavors Help Break Ground for Innovative Breast Cancer Treatments

May 18th 2022

Adam M. Brufsky, MD, PhD, emphasizes the importance of tyrosine kinase inhibitors in HER2-postive breast cancer and highlights the potential benefits of local salvage radiation therapy in patients with oligometastatic or de novo stage IV breast cancer.

Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial

May 18th 2022

Highlights from the OlympiA trial, which evaluated the use of olaparib in the adjuvant setting in patients with high-risk BRCA-mutated breast cancer.

Breast Cancer: The Evolving Neoadjuvant and Adjuvant Treatment Landscape

May 18th 2022

Joyce O'Shaughnessy, MD, provides a brief overview of novel neoadjuvant and adjuvant treatment approaches being investigated in the setting of breast cancer.

Institutional Perspectives in Cancer- Breast Cancer: Chaired by Erica Stringer-Reasor, MD

May 18th 2022